mercoledì 20 febbraio 2008

Il colmo per un calciatore?

Scendere in campo con le pantofole, sapendo di casa!!

Ti abbiamo donato un sorriso?

Vuoi donare 1 Euro o 2 Euro a favore del progetto scientifico "L'Officina del Cervello" condotto dal Prof. Angelo Vescovi per l'avvio della sperimentazione clinica per Sclerosi Laterale Amiotrofica*, Sclerosi Multipla e Lesioni Midollari?
*26 e 27 Febbraio

Invia un SMS Solidale (solo cellulari personali Vodafone, TIM, Wind e 3) al 48587 o chiama il 48587 da Rete Fissa Telecom Italia

Grazie da Neurothon

3 commenti:

laura1869 ha detto...

A questo indirizzo è pubblicato uno studio della John Hopkins University of Medicine sulle staminali
E la storia continua, a questo indirizzo è pubblicato uno studio sulle staminali dell'Università della California, approvato dalla FDA, avrà come target primario l'Atrofia Muscolare Spinale, e di conseguenza anche la SLA.

laura1869 ha detto...

E pensare che la California ha stanziato
3 MILIARDI DI DOLLARI, ripeto 3 MILIARDI per la ricerca delle staminali nel 2005, quindi da pochissimo.
E il Prof. Vescovi in Italia si sbatte per raccogliere 200.000 euro....

Anonimo ha detto...

Families of Spinal Muscular Atrophy; University of
California, Irvine Stem Cell Scientist; and California Stem
Cell Announce Collaboration for Safety Studies for Stem
Cell Therapy in Spinal Muscular Atrophy
Safety Studies Leading to FDA Application for Stem Cell Therapy
in SMA will begin in early 2008
February 19, 2008: Families of Spinal Muscular Atrophy (FSMA); a
stem cell scientist at University of California, Irvine (UCI); and
California Stem Cell, Inc. (CSC) are pleased to announce a partnership
to advance a potential stem cell therapy for SMA to human clinical
trials. The specific set of animal studies planned, which will be
conducted in accordance with FDA regulations, will assess the safety of
motor neuron progenitors derived from human stem cells after
SMA is a genetic disorder with no current treatment that is the leading
genetic killer of children younger than two years of age. SMA typically
is marked by the degeneration of voluntary muscle movement including
the muscles that control crawling, walking, swallowing or breathing due
to the dysfunction or death of motor neurons. It is a debilitating and
often fatal disease.
These safety studies are the critical steps in advancing stem cell therapy
into human trials for SMA. High purity human motor neuron
populations for use in transplant therapies were developed by CSC and
have been used successfully in proof of concept efficacy and preliminary
safety studies in the laboratory of Dr. Hans Keirstead at UCI with
funding from FSMA. CSC employs scalable manufacturing protocols to
produce and supply the large population of clinical-grade motor neuron
progenitors required for these pivotal studies and future human clinical
“This collaboration illustrates the breadth of skills that are required to
take a potential treatment from the bench to the bedside. I am confident
that we have assembled the right team and the right plan to move this
treatment forward with both diligence and speed,” said Hans S.
Keirstead, Professor, UCI.
“California Stem Cell is very pleased to be part of this collaboration
with Families of SMA and UCI and optimistic, based on preliminary
data, about the very real potential for success in developing a cell
transplant therapy for SMA, which devastates so many families.” said
Chris Airriess, Chief Operating Officer, CSC.
Studies are being conducted in parallel at both the Keirstead laboratory
at UCI and the laboratory of Dr. Douglas Kerr at Johns Hopkins
University, with funding from FSMA, to show the benefit of human
motor neuron progenitor replacement in animal models of motor neuron
disease. This builds on the pioneering work published by Dr. Kerr in the
Annals of Neurology in 2005 showing that transplants of mouse
embryonic stem cell-derived motor neurons into the spinal cord can
connect with muscles and partially restore function in paralyzed rats.
“This program holds a tremendous amount of promise for our patients
and families. While FSMA makes significant investments in traditional
and relatively low-risk drug approaches to find a treatment for SMA,
alternative therapies like stem cells may hold the key to a cure. Our
strategy is to fund both approaches in parallel to reach our goals as
quickly as possible while minimizing risks” said Kenneth Hobby,
Executive Director, FSMA. “Families of SMA is extremely grateful to
The Dhont Family Foundation for the support of $200,000 given to help
move this stem cell program forward.”
Stem cell therapy for SMA has the potential to replace the motor
neurons lost during the disease course. While other types of therapies
have the potential to slow disease progression and possibly increase
strength, motor neuron replacement through the use of stem cells is the
only means to replace motor neurons once they are gone.
This strategy may be useful for treating multiple disorders such as spinal
cord injury, transverse myelitis, and Amyotrophic Lateral Sclerosis
(ALS) in addition to Spinal Muscular Atrophy.
About Families of Spinal Muscular Atrophy:
Families of SMA is dedicated to developing a treatment and cure for
SMA by promoting and supporting research, helping families cope
through informational programs and support, and educating the public
and the medical community about SMA. The organization, originally
founded in 1984 by a small group of parents, has grown to more than 32
chapters and affiliates worldwide and more than 50,000 supporters.
FSMA receives the majority of its revenues through volunteer efforts,
funding almost $40 million to date for research. FSMA-sponsored
research has made significant contributions to better understanding SMA
and advancing new therapies towards human clinical testing. See for more information. Media contact:
or call 800 886-1762.
About California Stem Cell, Inc:
Irvine, CA based California Stem Cell, Inc is a privately held company
focused on the manufacturing of high purity human cells for therapeutic
development and clinical application. Founded in 2005, CSC has
developed proprietary methods for scalable production of human motor
neurons, neuronal progenitors, cardiac muscle and sino-atrial node cells.
Media contact:
About the University of California, Irvine:
The University of California, Irvine is a top-ranked university dedicated
to research, scholarship and community service. Founded in 1965, UCI
is among the fastest-growing University of California campuses, with
more than 27,000 undergraduate and graduate students, and nearly 2,000
faculty members. The third-largest employer in dynamic Orange
County, UCI contributes an annual economic impact of $3.6 billion. For
more UCI news, visit